News

Rakesh Jain, MD, and Greg Mattingly, MD, answered audience questions regarding the potential of GABA and glutamate modulation in understanding and treating the psychological impact of traumatic brain injury (TBI) in the frontal lobe, as well as positive insights on the newer depression treatment options available and the flexibility of those approac

Antidepressant prescribing patterns and outcomes for patients with major depressive disorder (MDD) vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.

Individuals with major depressive disorder (MDD) may have significant moderate cognitive deficits in executive function, memory, and attention, but not in reaction time, when compared to healthy subjects. Researchers published their findings from a recent comprehensive review and meta-analysis in Psychotherapy and Psychosomatics. 

Multilocus sequential repetitive transcranial magnetic stimulation (rTMS) reduced tinnitus symptom severity in both patients with and without comorbid major depressive disorder (MDD) in a recent open-label treatment study published in Neuromodulation.

The US Food and Drug Administration (FDA) approved Rejoyn, the first prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms.